RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Karyopharm Therapeutics Stock

Karyopharm Therapeutics Debt 2024

Karyopharm Therapeutics Debt

251.17 USD

Ticker

KPTI

ISIN

US48576U1060

WKN

A1W77U

In 2024, Karyopharm Therapeutics's total debt was 251.17 USD, a 49.86% change from the 167.6 USD total debt recorded in the previous year.

Karyopharm Therapeutics Aktienanalyse

What does Karyopharm Therapeutics do?

Karyopharm Therapeutics Inc. is a biopharmaceutical company based in Newton, Massachusetts. The company focuses its research and development on the use of selective inhibitors of nuclear export (SINE) for the treatment of cancer and inflammatory diseases. Karyopharm Therapeutics has been active in the field of biotechnology research since 2010. Karyopharm Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Karyopharm Therapeutics's Debt Structure

Karyopharm Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Karyopharm Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Karyopharm Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Karyopharm Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Karyopharm Therapeutics stock

What is the debt of Karyopharm Therapeutics this year?

Karyopharm Therapeutics has a debt level of 251.17 USD this year.

What was the debt of Karyopharm Therapeutics compared to the previous year?

The debt of Karyopharm Therapeutics has increased by 49.86% compared to the previous year increased.

What are the consequences of high debt for investors in Karyopharm Therapeutics?

High debt can pose a risk for investors of Karyopharm Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Karyopharm Therapeutics?

Low debt means that Karyopharm Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Karyopharm Therapeutics affect the company?

An increase in debt of Karyopharm Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Karyopharm Therapeutics affect the company?

A reduction in debt of Karyopharm Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Karyopharm Therapeutics?

Some factors that can influence the debt of Karyopharm Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Karyopharm Therapeutics so important for investors?

The debts of Karyopharm Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Karyopharm Therapeutics take to change the debt?

To change the debt, Karyopharm Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Karyopharm Therapeutics pay?

Over the past 12 months, Karyopharm Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Karyopharm Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Karyopharm Therapeutics?

The current dividend yield of Karyopharm Therapeutics is .

When does Karyopharm Therapeutics pay dividends?

Karyopharm Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Karyopharm Therapeutics?

Karyopharm Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Karyopharm Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Karyopharm Therapeutics located?

Karyopharm Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Karyopharm Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Karyopharm Therapeutics from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did Karyopharm Therapeutics pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of Karyopharm Therapeutics in the year 2023?

In the year 2023, Karyopharm Therapeutics distributed 0 USD as dividends.

In which currency does Karyopharm Therapeutics pay out the dividend?

The dividends of Karyopharm Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Karyopharm Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Karyopharm Therapeutics

Our stock analysis for Karyopharm Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Karyopharm Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.